Related Experiment Video
Updated: Jul 1, 2025
07:39
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
87
Non-receptor Type PTPases and their Role in Controlling Pathways Related to Diabetes and Liver Cancer Signalling
Nidhee Chaudhary1, Bellam Kiranmayee1
1Centre for Biotechnology & Biochemical Engineering, Amity Institute Biotechnology, Amity University Uttar Pradesh, Sector-125, Expressway, Noida, 201313, Uttar Pradesh, India.
Current Pharmaceutical Biotechnology
|February 29, 2024
Summary
Non-receptor Protein Tyrosine Phosphatases (PTPases) regulate insulin signaling, impacting diabetes and liver cancer (HCC). Targeting PTPases may offer new treatments for these conditions.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Non-receptor Protein Tyrosine Phosphatases (PTPases) are key regulators of cellular signaling pathways.
- Insulin signal transduction is crucial for glucose homeostasis and is modulated by tyrosine phosphorylation.
- Insulin resistance is linked to metabolic disorders and the development of Hepatocellular Carcinoma (HCC).
Purpose of the Study:
- To elucidate the role of non-receptor type PTPases in insulin signaling.
- To explore the connection between PTPase activity, insulin resistance, and HCC pathogenesis.
- To identify PTPases as potential therapeutic targets for diabetes and HCC.
Main Methods:
- Review of literature on PTPase function in insulin signaling.
- Analysis of molecular mechanisms linking insulin resistance and HCC.
- Identification of specific PTPases (e.g., PTP1B, SHP-2) involved in these pathways.
Main Results:
- Non-receptor PTPases, such as PTP1B and SHP-2, negatively regulate insulin signaling.
- Reduced PTPase activity can enhance insulin sensitivity and potentially combat insulin resistance.
- Dysregulated insulin signaling in insulin-resistant states promotes HCC growth by increasing glucose availability.
Conclusions:
- Non-receptor PTPases are critical regulators of insulin signaling and play a significant role in diabetes and HCC.
- Inhibition of specific PTPases presents a promising therapeutic strategy for managing insulin resistance and treating HCC.
- Further research into PTPase-mediated pathways could yield novel anti-cancer and anti-diabetic agents.
More Related Videos
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:28Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
01:19Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
01:22Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K